Moreover, BRG1 (SMARCA4), a chromatin remodeling ATPase, is essential for the survival and proliferation of PTEN-deficient prostate cancer cells, as demonstrated by Ding et al. The study indicates that BRG1 also contributes to metastatic potential, with in vivo experiments showing that silencing BRG1 significantly reduces bone colonization and osteolysis in mouse models, highlighting its role in promoting bone metastasis and suggesting it as a potential therapeutic target for inhibiting skeletal metastasis [94]. Here, SMARCA4 is linked to prostate carcinoma.